Niacin, atherosclerotic disease and low LDL

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
http://www.nejm.org/doi/full/10.1056/NEJMoa1107579?query=OF

Among patients with atherosclerotic cardiovascular disease and LDL cholesterol levels of less than 70 mg per deciliter (1.81 mmol per liter), there was no incremental clinical benefit from the addition of niacin to statin therapy during a 36-month follow-up period, despite significant improvements in HDL cholesterol and triglyceride levels. (Funded by the National Heart, Lung, and Blood Institute and Abbott Laboratories; AIM-HIGH ClinicalTrials.gov number, NCT00120289.)